Drugs That Fight MERS-coronavirus Revealed

A number of existing pharmaceutical drugs and compounds under development may be effective against the Middle East Respiratory Syndrome, researchers have found

A number of existing pharmaceutical drugs and compounds under development may be effective against the Middle East Respiratory Syndrome, researchers have found.

In the first study, researchers screened a library of 290 pharmaceutical drugs, either FDA-approved or in advanced clinical development for antiviral activity against the MERS coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV) in cell culture. They found 27 compounds that were active against both viruses including some cancer drugs and antipsychotics.

Patient-to-nurse Infection of Coronavirus: First Proof
The World Health Organization said that two Saudi health workers have contracted the deadly coronavirus from patients, marking the first evidence of transmission in a hospital setting.

Matthew Frieman of the University of Maryland Medical School said repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to the normal paradigm of huge library screening against a specific viral enzyme.

He said given development times and manufacturing requirements for new products, repurposing of existing drugs is likely the best solution to rapidly identify therapeutics for outbreaks due to emerging viruses.

In the second study, researchers collaborating in the European antiviral research program SILVER used a similar methodology to screen a library of 348 FDA-approved drugs for anti-MERS-CoV activity in cell culture. They identified four compounds that inhibited MERS-CoV, SARS-CoV and Human Coronavirus 229E at relatively low concentrations.

Saudi Confirms 61 MERS Coronavirus Death Toll
With the death of an elderly woman from the MERS coronavirus, the death toll from the respiratory disease in Saudi Arabia has risen to 61 Saudi health authorities said.

Two of the compounds were also identified by the U.S. study: the antimalarial drug chloroquine and the antipsychotic chlorpromazine.

The third and final study finds that an experimental compound, previously shown to block SARS-CoV replication, can inhibit replication of two other coronaviruses, MERS-CoV and mouse hepatitis virus.